C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 5/18 (2006.01) A61K 39/395 (2006.01) C07K 16/24 (2006.01) C07K 16/28 (2006.01) C07K 16/46 (2006.01) G01N 33/53 (2006.01) G01N 33/569 (2006.01) G01N 33/576 (2006.01) G01N 33/577 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2225852
This invention relates to an anti-Fas ligand antibody and an assay method utilizing the anti-Fas ligand antibody. More specifically, this invention relates to a method for assaying a Fas ligand in human body fluid utilizing an anti-Fas ligand antibody, and the antibody adapted for use in such an assay. This invention also relates to an anti--Fas ligand antibody that exhibits high suppression of the Fas ligand-induced apoptosis. This invention also relates to a hybridoma or a cell line that produces such an antibody. An object of the present invention is to provide an anti-Fas ligand antibody and an assay method utilizing such an antibody, and in particular, a method for assaying a Fas ligand in human body fluid using an anti-Fas ligand antibody, and an antibody adapted for use in such assay method. Another object of the present invention is to provide an anti-Fas ligand antibody exhibiting high, for example 50% or higher, suppression of the apoptosis induced by the Fas ligand, and said antibody which is a humanized antibody. A further object of the present invention is to provide a hybridoma and a cell line producing such an antibody. Furthermore the present invention also provides novel compositions or medicaments containing as an indispensable element or an active ingredient at least any one of afore-mentioned anti-Fas ligand antibodies of the invention, and methods of treating systemic or topical pathological conditions or a disease with, caused by or involving the abnormality of Fas/Fas ligand system or of apoptosis through Fas antigen, and also involving to inject therapeutically-effective of an anti-Fas ligand antibody to suppress apoptosis of Fas antigen-expressing cells into a patient.
L'invention, qui concerne, d'une part un procédé d'épreuve, notamment de ligands de Fas dans un fluide corporel humain, faisant intervenir un anticorps de ligand antiFas, l'anticorps à utiliser dans ce procédé, un réactif d'épreuve, un kit d'épreuve et, d'autre part un anticorps de ligand antiFas doué d'un fort pouvoir d'inhibition (par exemple selon un rapport égal ou supérieur à 50%) à l'encontre d'une apoptose due à des ligands de Fas ainsi que l'anticorps de ligand antiFas qui est un anticorps humanisé, a également trait à un hybridome ou à une lignée cellulaire produisant l'anticorps, à une composition ou à un médicament comportant, comme principal composant ou ingrédient actif, au moins l'un des anticorps de ligand antiFas. L'invention porte également sur une technique de traitement d'affections ou de maladies généralisées ou topiques présentant des anomalies au sein du système antigène de Fas/ligand de Fas ou au niveau de l'apoptose induite par l'antigène Fas, celles-ci étant susceptibles, soit d'accompagner ces affections ou maladies, soit de les déclencher, soit d'y participer. La technique consiste à administrer à un patient une quantité efficace, du point de vue thérapeutique, de l'anticorps de ligand antiFas à même d'inhiber l'apoptose de cellules dans lesquelles le ligand de Fas exprime un antigène de Fas.
Co Man Sung
Matsusue Tomokazu
Nagata Shigekazu
Shirakawa Kamon
Vasquez Maximiliano
Mochida Pharmaceutical Co. Ltd.
Osaka Bioscience Institute
Smart & Biggar
LandOfFree
Anti-fas ligand antibody and assay method using the anti-fas... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-fas ligand antibody and assay method using the anti-fas..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-fas ligand antibody and assay method using the anti-fas... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1786009